SEP 25, 2015 03:13 PM PDT

New Drug and Native Flora Combat C. difficile

WRITTEN BY: Kerry Evans
Clostridium difficile is a Gram positive, rod-shaped bacterium commonly found in the soil.  However, a small number of people, about 1 in 20, also house C. difficile in their guts. This usually isn’t a problem, but the bacteria can produce toxins that cause severe cases of colitis, diarrhea, and sometimes death. These infections typically occur in cases where the normal gut flora has been depleted by antibiotics, allowing C. difficile to “take over”.   

Since antibiotics often promote C. difficile infections, they aren’t much use in combating these bacteria. This has left researchers searching for other treatment options, and scientists at Stanford University School of Medicine have taken a unique approach.
 
C. difficile infection causes severe colitis and diarrhea.


Instead of searching for a way to kill C. difficile directly, Matthew Bogyo, Ph.D., used a small molecule called ebselen to disarm C. difficile toxins.  These toxins enter the cells lining the gut and induce an inflammatory response, resulting in colitis and diarrhea.  This proinflammatory response also prevents the normal flora from repopulating the gut.  

Bogyo and colleagues showed that ebselen had a direct effect on the activity of C. difficile toxins by incubating purified toxin with or without ebselen, and then injecting the mixtures into mice.  After three days, all of the mice injected with toxin alone died, while the mice injected with the ebselen and toxin mixture survived.  Bogyo then tested a more clinically relevant model of infection.  They first treated mice with antibiotics to mimic the conditions under which C. difficile infections occur.  Following antibiotic treatment, they infected mice with a highly virulent, drug-resistant strain of C. difficile, and treated them orally with ebselen.  The mice treated with ebselen survived the infection with little evidence of damage to the colon.  

Thus, ebselen both prevented damaging colitis and diarrhea, and allowed the normal flora to outcompete C. difficile.  What’s more, ebselen has already been tested in clinical trials to treat hearing loss in chemotherapy patients.  This means ebselen could be on the fast track to treating C. difficile infections.  

Ebselen isn’t the only unique approach to treating C. difficile. Fecal transplant, as explained in this video, has been highly successful in treating C. difficile infections.  

Sources: Science Daily, Science Translational Medicine, Wikipedia, Cleveland Clinic
 
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
OCT 05, 2018
Videos
OCT 05, 2018
Listeria Infections Linked to Deli Ham
The CDC has some advice about a ham recall announced on October 3 by Johnston County Hams, Inc....
OCT 19, 2018
Microbiology
OCT 19, 2018
A Newly Discovered Bacterial Toxin Reveals More About Bacterial Warfare
Even bacteria have to use self-defense. Some deploy toxins that they can use to dominate other microbial competitors....
NOV 15, 2018
Videos
NOV 15, 2018
A Season of Outbreaks
In a few different places around the world, people are facing disease outbreaks due to pathogenic microbes....
NOV 21, 2018
Microbiology
NOV 21, 2018
Human Antibody That can Neutralize West Nile Virus is Found
In 1999, there were 62 cases of West Nile Virus in New York State. Since then it has spread around the United States....
NOV 25, 2018
Videos
NOV 25, 2018
Ongoing Ebola Outbreak in DRC Becomes Country's Worst Ever
On August 1, 2018, an Ebola outbreak was declared in the Democratic Republic of the Congo, which is still ongoing....
DEC 11, 2018
Genetics & Genomics
DEC 11, 2018
Dust with High Levels of Triclosan has More Antibiotic Resistance Genes
Researchers have found that some dust contains high amounts of a common antimicrobial agent called triclosan....
Loading Comments...